Table 1. Clinical characteristics of CML patients.

Characteristics (n = 93)	Median (range)
Age (yr)	60.1 (23–85)
Male/female	58/35
Sokal risk (low/int./high)	59/24/4
EUTOS risk (low/high)	73/5
Prior IFN-α (+/−)	19/74
CML duration (mo)	84.8 (13.2–229.4)
Duration of IM treatment (mo)	75.7 (12.6–122.4)
Actual daily IM dose (mg/d)	400 (66.7–400)
Median time to CCyR (mo)
From diagnosis to CCyR	6.6 (1–103.3)
From IM therapy to CCyR	5.3 (0.5–76.7)
Median time to MMR (mo)
From diagnosis to MMR	19.5 (4.4–185.6)
From IM therapy to MMR	17.0 (3.2–93.9)

CCyR, complete cytogenetic response; EUTOS, European Treatment and Outcome Study; IM, imatinib; int., intermediate; MMR, major molecular response.